Novo co-led the series C round with Longitude Capital and Checkmate will use the cash to advance clinical development of its lead asset, which is targeting melanoma.

The Bloomberg-backed data science management platform increased its overall funding to $128m in a round featuring Dell Technologies Capital.

Dell Technologies Capital and Wipro Ventures contributed to a round that advanced the total raised by the open source database software provider to $55m.

OHSU's CNS disorder drug developer has launched with $76m from investors co-led by Arch Venture Partners and Cowen Healthcare Investments.

The CNS disorder drug developer has launched with $76m from investors including Biogen, Bristol Myers Squibb and Pfizer Ventures.

GV co-led a series C round for the healthcare collaboration service together with F-Prime Capital, Andreessen Horowitz and Transformation Capital, taking its overall funding past $101m.

The Legend Capital-backed auto parts e-commerce marketplace boosted its total funding to $110m in a $56.6m round led by Huaxing Growth Capital Fund.

Stanford’s lysosome protein degradation spinout Lycia emerged with $50m of capital from Versant Ventures to develop a portfolio of drug candidates.

Varian Medical Systems and Johnson & Johnson Innovation – JJDC have returned for the series C-1 round having backed the U-M spinout's series C last year.

Varian Medical Systems and Johnson & Johnson Innovation – JJDC returned for the series C-1 round having backed the histotripsy technology developer's series C last year.